

PHOSPHATE SUPPLEMENTATION IN ADULT

ORAL

DRUGS	SODIUM DIHYDROGEN PHOSPHATE (NaH ₂ PO ₄) - Non-standard item	JOULIE'S SOLUTION - Standard item
CONTENT	1ml: 2 mmol phosphate + 2 mmol sodium ion	1ml: 1 mmol phosphate + 0.76 mmol sodium ion
DOSE	Initiate therapy with 30 to 80 mmol of phosphate per day in divided doses , then adjusted accordingly based on serum phosphate level ⁶	
	Example: 5ml TDS (30 mmol/day)	Example: 10ml TDS (30 mmol/day)

INTRAVENOUS

DRUGS	POTASSIUM DIHYDROGEN PHOSPHATE (KH ₂ PO ₄) Standard item	SODIUM GLYCEROPHOSPHATE (GLYCOPHOS) Standard khusus [Total Parenteral Nutrition (TPN)]
CONTENT	1 ampoule: 10ml 1ml: 1 mmol phosphate + 1 mmol potassium + 2 mmol hydrogen ion ⁵	1 vial: 20ml 1ml: 1 mmol phosphate + 2 mmol sodium ion ⁵
DOSE	Severe hypophosphatemia: Up to 10 mmol phosphate over 12 hours, may be repeated at 12-hour intervals until serum phosphate exceeds 0.3 mmol/L ¹	The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol/day ³
DILUTION AND ADMINISTRATION	Dilute up to 10 mmol phosphate in 100 ml ⁷ or 250 ml NS/D5 ⁸ **For peripheral line, should not exceed 10 mmol/250 ml IV infusion: <ul style="list-style-type: none"> • May administer at rates up to 20mmol/hour⁸ (for patients with severe hypophosphatemia) • Administer over 4 – 6 hours² (for patients with renal dysfunction and/or less severe hypophosphatemia) • May administer over duration up to 12 hours¹ 	IV infusion: Dilute and give via an infusion pump over at least 8 hours . Concentrated solutions (e.g: 20 mmol in 50 ml) must be given via central venous access device due to high osmolarity ⁴ For administration via a central venous access device ⁴ : <ul style="list-style-type: none"> • Dilute 20 mmol phosphate (1 vial) in 50ml NS/D5 (0.4mmol/ml) • Dilute 20 mmol phosphate (1 vial) in 100ml NS/D5 (0.2mmol/ml) For peripheral administration ⁴ : <ul style="list-style-type: none"> • Dilute to a maximum concentration of 0.1 mmol phosphate in 1ml. Suggestion: dilute 40 mmol phosphate (2 vials) in 500ml

REFERENCES:

- 1) DBL Potassium Dihydrogen Phosphate.(2022).MIMS *Online*. Retrieved from: <https://www.mims.com/malaysia/drug/info/dbl%20potassium%20dihydrogen%20phosphate>
- 2) Lexicomp. (n.d.). Potassium phosphate: Drug information. UpToDate. Retrieved August 1st, 2022, from <https://www.uptodate.com/contents/potassium-phosphate-drug-information>
- 3) Glycophos® 306.1 mg/mL Infusion, concentrate, New Zealand Data Sheet <https://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdf>
- 4) Sodium glycerophosphate concentrate (Glycophos) published: 03/12/2019 https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=103553
- 5) Hospital USM Formulary. Retrieved from: <http://dformulary.h.usm.my/>
- 6) Alan SL Yu, MB, Bchir, Jason R Stubbs (2021). Hypophosphatemia: Evaluation and treatment, UpToDate. Retrieved August 1st, 2022, from <https://www.uptodate.com/contents/hypophosphatemia-evaluation-and-treatment>
- 7) Critical Care Pharmacy Handbook 2nd Edition 2020, Pharmaceutical Services Programme, Ministry of Health Malaysia
- 8) Dilution Guide for High Alert Medications 2011, Pharmaceutical Services Division, Ministry of Health Malaysia

Prepared by:

Syahira Afiqah binti Mohamad Pauzi
Nur Aida Murni binti Mamamad
Nazirah binti Rajat

Edited by:

Khairul Bariah Johan @ Rahmat